[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636820":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":27,"collaborators":11,"id":29,"slug":11,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":11,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":45,"conditions":46,"keywords":51,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"COMPASS Pathways","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"1 mg COMP360 psilocybin","ACTIVE_COMPARATOR",null,[13],"Drug: COMP360 psilocybin",{"label":15,"type":16,"description":11,"interventionNames":17},"10 mg COMP360 psilocybin","EXPERIMENTAL",[13],{"label":19,"type":16,"description":11,"interventionNames":20},"25 mg COMP360 psilocybin",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","COMP360 psilocybin","COMP360 psilocybin administered with monitoring and support",[9,15,19],{"type":28,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636820",false,"NCT07570654","Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","A Phase 2b\u002F3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","Redefine","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with PTSD at least 6 months ago\n\nExclusion Criteria:\n\n\\- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions","ALL","18 Years",{"count":39,"type":40},300,"ESTIMATED","INTERVENTIONAL",[43,44],"PHASE2","PHASE3","The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.",[47,48,49,50],"PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder",[52,53,34,48,54],"COMP360","psilocybin","trauma","NOT_YET_RECRUITING","2026-05-08",{"date":58,"type":59},"2026-05-12","ACTUAL",{"date":61,"type":40},"2026-09",{"date":63,"type":40},"2029-09",{"name":5,"class":6}]